Tectonic Therapeutic, Inc.
NASDAQ:TECX · NASDAQ Global Market
-$0.29 today
Vol 0.10M · Avg 0.20M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-29.5%
avg -67.4%
ROIC
-33.3%
avg -1422.1%
ROA
-28.4%
avg -73.8%
Analysis
ROA is currently the strongest return metric at -28.4% versus its period average of -73.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Alise S. Reicin | President, Chief Executive Officer, Secretary & Director | $1.03M | — | 65 | $311,547.00 | 1.65% |
Daniel Lochner | Chief Financial Officer | $728,712.00 | — | 43 | $7,500.00 | 0.04% |
Marcella K. Ruddy | Chief Medical Officer | $723,250.00 | — | 62 | $67,682.00 | 0.36% |
Timothy A. Springer | Co-Founder & Independent Director | $24,000.00 | — | 77 | $10,200.00 | 0.05% |
Marc Schwabish | Chief Business Officer | — | — | 46 | $45,314.00 | 0.24% |
John Diener | Senior Vice President of Antibody Engineering & Protein Sciences | — | — | — | — | — |
Anthony Muslin | Chief Development Officer | — | — | — | — | — |
Washington Alves | Senior Vice President of Technical Operations | — | — | — | — | — |
Geraldine Peters-Wiles | Senior Vice President of Human Resources | — | — | — | — | — |
Peter McNamara | Chief Scientific Officer | — | — | 54 | $8,045.00 | 0.04% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
3
$235,160.00
Sells
7
$629,561.94
Net Sentiment
$394,401.94
Net selling
Most Active
McNamara Peter
4 transactions
Analysis
Insiders reported 3 buys worth $235,160.00 and 7 sells worth $629,561.94 over the last 12 months. That adds up to net selling of $394,401.94. McNamara Peter was the most active insider with 4 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A6 analysts |
| Revenue | N/A | N/A | N/A | N/A6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Alpha Tau Medical Ltd.
NASDAQ:DRTS
$868.76M
Alto Neuroscience, Inc.
NYSE:ANRO
$779.79M
DBV Technologies S.A.
NASDAQ:DBVT
$383.25M
Amarin Corporation plc
NASDAQ:AMRN
$337.34M
Silence Therapeutics plc
NASDAQ:SLN
$324.73M
Cellectis S.A.
NASDAQ:CLLS
$316.31M
Larimar Therapeutics, Inc.
NASDAQ:LRMR
$301.66M
Lyell Immunopharma, Inc.
NASDAQ:LYEL
$297.79M
AC Immune S.A.
NASDAQ:ACIU
$240.69M
Aldeyra Therapeutics, Inc.
NASDAQ:ALDX
$117.02M
Who manages TECX?
Tectonic Therapeutic, Inc. (TECX) lists 10 active executives. The top listed executive is Alise S. Reicin, President, Chief Executive Officer, Secretary & Director.
Are TECX insiders buying or selling?
Recent insider activity shows net buying of $86.00M.
Explore More
Continue the stock analysis
Jump to another research area for this company.